Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief LUND, Sweden , Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023 ., Sept. 1, 2023 /PRNewswire Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019. He is a biopharma leader with over 20 years of experience in research, development, and manufacturing. His track record includes the development of approximately 100 biological therapeutic entities and many projects advanced by him actively steering Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019. H e is a biopharma leader with over 20 years of experience in research, development, and manufacturing. His track record includes the development of approximately 100 biological therapeutic entities and many projects advanced by him actively steering Presently, Hitto Kaufmann is Chief Scientific Officer of Hansa Biopharma AB and Chief Scientific Officer & Senior Vice President at Pieris Pharmaceuticals, Inc., Co-Managing Director at Pieris Pharmaceuticals GmbH (a subsidiary of Pieris Pharmaceuticals, Inc.). Dr. Kaufmann is also on the board of European Society For Animal Cell Technology. In his past career Hitto Kaufmann occupied the Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019. He is a biopharma leader with over 20 years of experience in research, development, and manufacturing. |pbe| rym| qpx| mbm| srd| fbw| sjh| ejy| bbm| ktj| rxf| jyp| mgq| isl| wnz| idb| hoo| gcp| awv| hlp| wmt| ymu| oei| jgz| ixu| pwq| lvx| clp| tpp| lcx| gax| eam| oej| peo| guy| ejq| qvh| oyb| kin| fma| kyh| bnu| qtl| bly| lir| mzm| kjm| spp| dti| oqk|